4 results about "Myeloblastic leukemia" patented technology

Methods of predicting whether a subject with chronic myelogenous leukaemia (CML) is at risk of relapse following cessation of a treatment for CML, whether a subject with CML will achieve TFR following cessation of a treatment for CML, and selecting a subject for treatment, wherein the subject has CML or has been diagnosed with CML are disclosed herein. The methods comprise determining the expression of one or more genes regulated by PRC1. Also provided are kits and antigen-binding molecules suitable for use in the disclosed methods.

The invention relates to the treatment of chronic myeloid leukemia (CML). In particular it relates to the treatment of CML with inhibitors of mitochondrial pyruvate transport, which are able to target leukemic stem cells (LSCs) which are resistant to therapy with tyrosine kinase inhibitors (TKIs). Combination therapies with BCR-ABL kinase inhibitors are also described.

The invention discloses a targeted protein degradation agent utilizing an autophagy-lysosome pathway as well as a preparation method and application of the targeted protein degradation agent, and belongs to the technical field of degradation agent preparation. The preparation method comprises the following steps: carrying out nucleophilic substitution reaction on a GW5074 derivative and a linker arm precursor to obtain a GW5074 derivative-linker arm intermediate, and coupling the GW5074 derivative-linker arm intermediate with demethylated imatinib to obtain the targeted protein degradation agent utilizing the autophagy-lysosome pathway. The protein degradation agent disclosed by the invention is relatively few in preparation steps, easy to synthesize and relatively high in yield, and can be used for preparing medicines for treating cancers, particularly antitumor medicines for treating chronic granulocytic leukemia.

The present invention provides an H3S28 phosphorylation inhibitor or a composition containing the same. [Solution] A histone H3 phosphorylation inhibitor comprising a benzaldehyde compound or a pharmaceutically acceptable salt thereof is provided. The inhibitor or a composition comprising the same can be used to prevent, treat, or treat various cancers involving the H3S28ph protein (e.g., hepatic cancer, pancreatic cancer, lung cancer, ovarian cancer, colon adenocarcinoma, chronic myeloid leukemia, pancreatic ductal adenocarcinoma, malignant kidney tumor, breast cancer, melanoma, etc.), radiation-resistant cancers of these cancers, heart failure, and their complications, or to treat poor prognoses, by inhibiting the expression of the H3S28ph protein. Preferably, the benzaldehyde compound is benzaldehyde, 5,6-O-benzylidene-L-ascorbic acid, monosodium 5,6-O-benzylidene-L-ascorbic acid, 4,6-O-benzylidene-D-glucopyranose, or N-benzylideneethylamine.